The Drawdown Was on Fear. The Numbers Were on a Different Track

Agilent Technologies lost nearly 30% of its stock value between January and late March 2026. The market was pricing in a story that felt real at the time: China collapsing, academic and government spending frozen, and tariffs about to eat margins. The stock hit a 52-week low of $108.35.

What the tape did not show is that Agilent's operating business did not break. Quarter by quarter, it got harder to dismiss.

Q1 FY2026 (January 2026): Revenue of $1.80 billion. Raised the full-year revenue outlook for the first time.

Q2 FY2026 (April 2026): Revenue hit $1.83 billion — 6.3% core growth, beating the top end of guidance by 80 basis points. Operating margin expanded 130 basis points to 26.4%. Raised guidance again. Non-GAAP EPS of $1.49, beating the $1.41 consensus.

Q3 FY2026 (July 2026): Revenue climbed to $1.88 billion — 7.3% core growth. Operating margin hit 27.2%, up 210 basis points year-over-year, excluding a one-time $20 million tariff refund benefit. Raised guidance for the third consecutive quarter. China, the segment that terrified investors six months earlier, grew 9%, outperforming flat expectations.

Three quarters of raised guidance. Three quarters of expanding margins. The stock is now at $151, up roughly 40% from its low.

The question for a reader looking at this today is not whether the business has improved — the numbers say it has. The question is whether the operating story is real enough to justify the valuation, or whether the market's recovery has already priced in everything worth pricing.

The margin engine is structural, not seasonal

The margin expansion is the single number that carries this case. Operating margins went from roughly 25% a year ago to 27.2% in the most recent quarter. That is not the kind of bounce that happens because one quarter's comparables were soft. Management attributes it to something they call the Ignite operating system — a multi-year program that doubled pricing realization, cut procurement costs, and simplified the organization.

Pricing alone contributed about 200 basis points of margin in Q2 and continued into Q3. Agilent had originally targeted 100 basis points for the full year. They hit the original annual goal in one quarter.

The full-year FY2026 guidance expects over 100 basis points of operating margin expansion at the midpoint. When you combine that with revenue guidance raised to $7.49–$7.51 billion (6.0% core growth at the top end), you get an earnings picture that looks very different from the one the stock was pricing at its low.

Full-year non-GAAP EPS guidance: $6.12 to $6.15, excluding the tariff refund benefit. That is roughly 12% year-over-year EPS growth on top of expanding margins and revenue growth — all while the market spent months worrying about the company's cost structure.

Free cash flow is the hard proof

A margin story is not enough on its own. The question is whether the improved operating performance converts to actual cash in the bank.

Agilent generated $1.27 billion in free cash flow over the trailing twelve months, up 16.5% year-over-year. Free cash flow margin sits at 15%. For the full year, management guides to $1.6–$1.7 billion in operating cash flow with capital expenditures lowered to roughly $450 million.

In Q3 alone, free cash flow was $439 million with a 96% conversion rate from operating cash flow. The balance sheet shows $1.76 billion in cash, $6.6 billion in total debt, and a net leverage ratio of roughly 1 turn. That is a company that generates more than enough cash to service its debt and still fund acquisitions and return capital to shareholders.

This is the bridge between the margin story and the valuation question. A company that grows revenue in the low double digits, expands margins by 100+ basis points structurally, and converts nearly all of that into free cash flow — that is not a fragile business that just got lucky with one quarter. That is a business that is generating financial proof that the market's earlier fear was overstated.

The Biocare acquisition changes the revenue mix

In March, Agilent announced the acquisition of Biocare Medical for $950 million in cash. The deal closed in late June. Biocare is a global leader in immunohistochemistry (IHC) and molecular pathology — the lab tests that pathologists use to diagnose cancer.

The strategic logic is straightforward: Agilent already builds the Omnis automated IHC platform. Biocare supplies the reagents that run inside it. Combine the hardware with the consumables and you get higher recurring revenue — the kind of revenue that sticks around even when instrument purchases slow down.

Biocare contributed $10 million in revenue in Q3 and is expected to add $23 million in Q4. Management expects the deal to be accretive to EPS roughly 12 months after closing. The $950 million price tag is material but manageable: at roughly 0.6 turns of guided operating cash flow, it does not strain the balance sheet.

More importantly, the acquisition shifts Agilent's revenue mix toward diagnostics and recurring consumables. A higher proportion of recurring revenue means more predictable cash flows and less exposure to cyclical instrument purchasing cycles. That is a quality improvement that forward multiples tend to reward.

The valuation still asks a question

Here is where the story meets the math. Agilent trades at a trailing P/E of roughly 30x and a forward P/E of 37x. The forward price-to-free-cash-flow multiple is approximately 26.5x. Enterprise value to trailing EBITDA sits at 23.4x.

These are not cheap multiples. They are premium multiples for a premium business.

The argument in favor is that Agilent delivers exactly the kind of quality that commands a premium: low-double-digit revenue growth, expanding margins, strong free cash flow conversion, a growing recurring revenue base from the Biocare integration, and 13 consecutive years of dividend increases. The PEG ratio of 1.56 suggests the multiple is not absurd relative to the growth rate.

The argument against is that a forward P/E of 37x leaves little room for a misstep. If China reverses, if academic spending stays weak, if the instrument replacement cycle runs its course, the multiple can compress quickly. Morgan Stanley's March 2026 analysis explicitly flagged that Agilent traded at a 2x premium to peer multiples, and they cut their price target from $180 to $160 on multiple contraction alone — not because they thought the business was worse, but because they thought the premium was unsustainable.

There is also the matter of headwinds that haven't fully cleared. The food segment declined 3% in Q2 and was guided to low-single-digit declines for the full year, driven by funding delays in Asia. Academic and government spending fell 5% in Q2, and management has not declared that the multiyear grant uncertainty has resolved.

What the setup actually is

This is not a beaten-down recovery story anymore. The stock has recovered the vast majority of its drawdown. The old story — that Agilent was trapped between China exposure and expensive valuation — has been replaced by a newer one: a margin-expanding, cash-generating business that bought its way into a higher-quality revenue mix.

The setup for a new buyer is less about finding value in a fall and more about whether the quality is worth the premium. The free cash flow trajectory, the structural margin expansion from Ignite, the Biocare integration, and the recovery in China all point in the same direction. But they point into a stock that already trades at a premium multiple and has already run back from its low.

The thing that could change the reading is whether the FY2027 outlook, which management has not yet given, confirms that the margin expansion and China recovery are durable rather than transitional. The instrument replacement cycle is real but finite. The GLP-1 and pharma reshoring tailwinds are genuine but concentrated in specific end markets. If those tailwinds sustain through 2027 and beyond, the premium is earned. If they fade, the multiple compresses.

The break condition is the one that always matters in a case like this: free cash flow below the $1.6 billion guided range, combined with a reversal of the margin trajectory. If that happens, the operating story loses its proof and the valuation becomes the problem again. Until then, the numbers are doing what the market feared they wouldn't — they're getting better.